BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26197476)

  • 1. Association of Anti-GT1a Antibodies with an Outbreak of Guillain-Barré Syndrome and Analysis of Ganglioside Mimicry in an Associated Campylobacter jejuni Strain.
    Zhang M; Gilbert M; Yuki N; Cao F; Li J; Liu H; Li Q; Meng F; Zhang J
    PLoS One; 2015; 10(7):e0131730. PubMed ID: 26197476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies.
    Islam Z; Gilbert M; Mohammad QD; Klaij K; Li J; van Rijs W; Tio-Gillen AP; Talukder KA; Willison HJ; van Belkum A; Endtz HP; Jacobs BC
    PLoS One; 2012; 7(8):e43976. PubMed ID: 22952833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current cases in which epitope mimicry is considered a component cause of autoimmune disease: Guillain-Barré syndrome.
    Yuki N
    Cell Mol Life Sci; 2000 Apr; 57(4):527-33. PubMed ID: 11130452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mimicry in Campylobacter jejuni: role of the lipo-oligosaccharide core oligosaccharide in inducing anti-ganglioside antibodies.
    Perera VN; Nachamkin I; Ung H; Patterson JH; McConville MJ; Coloe PJ; Fry BN
    FEMS Immunol Med Microbiol; 2007 Jun; 50(1):27-36. PubMed ID: 17374131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome.
    Koga M; Takahashi M; Masuda M; Hirata K; Yuki N
    Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
    Yuki N
    Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campylobacter coli enteritis and Guillain-Barré syndrome: no evidence of molecular mimicry and serological relationship.
    Funakoshi K; Koga M; Takahashi M; Hirata K; Yuki N
    J Neurol Sci; 2006 Jul; 246(1-2):163-8. PubMed ID: 16600306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
    Komagamine T; Yuki N
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):391-400. PubMed ID: 16918391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes.
    Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC
    Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
    Yuki N
    J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactive epitopes present in campylobacter jejuni serotypes isolated from enteritis patients.
    Grozdanova A; Poceva-Panovska A; Brezovska K; Trajkovska-Dokic E; Dimovski A; Apostolski S; Suturkova Lj
    Prilozi; 2011; 32(1):113-25. PubMed ID: 21822182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.
    Koga M; Gilbert M; Li J; Koike S; Takahashi M; Furukawa K; Hirata K; Yuki N
    Neurology; 2005 May; 64(9):1605-11. PubMed ID: 15883324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of Guillain-Barré syndrome following a family outbreak of Campylobacter jejuni enteritis.
    Ang CW; van Doorn PA; Endtz HP; Merkies IS; Jacobs BC; de Klerk MA; van Koningsveld R; van der Meché FG
    J Neuroimmunol; 2000 Nov; 111(1-2):229-33. PubMed ID: 11063843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.
    Bowes T; Wagner ER; Boffey J; Nicholl D; Cochrane L; Benboubetra M; Conner J; Furukawa K; Furukawa K; Willison HJ
    Infect Immun; 2002 Sep; 70(9):5008-18. PubMed ID: 12183547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome.
    Jacobs BC; Koga M; van Rijs W; Geleijns K; van Doorn PA; Willison HJ; Yuki N
    J Neuroimmunol; 2008 Feb; 194(1-2):181-90. PubMed ID: 18178257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
    Prendergast MM; Moran AP
    J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.
    Koga M; Takahashi M; Yokoyama K; Kanda T
    J Neurol; 2015 Aug; 262(8):1954-60. PubMed ID: 26050638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?
    Yuki N; Koga M; Hirata K
    Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope.
    Nachamkin I; Liu J; Li M; Ung H; Moran AP; Prendergast MM; Sheikh K
    Infect Immun; 2002 Sep; 70(9):5299-303. PubMed ID: 12183587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.
    Yuki N
    Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.